 |
|
|
| |
Long-Term Follow-up of Patients With Chronic HCV Infection Following Treatment With Direct-Acting
Antiviral Regimens: Maintenance of SVR, Persistence of Resistance Mutations, and Clinical Outcomes
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Eric Lawitz,1 Peter Ruane,2 Catherine Stedman,3 Graham R. Foster,4 Robert H. Hyland,5 Sarah Coogan,5 Stephanie Moody,6 Hadas Dvory-Sobol,5
Steven J. Knox,5 Diana M. Brainard,5 Armando Abergel,7 Kosh Agarwal,8 Ziad Younes,9 Christian Schwabe10
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, USA; 2Ruane Medical and Liver Health Institute, Inc., Los Angeles, California, USA; 3Christchurch Hospital, Christchurch, New Zealand; 4Blizard Institute, Queen Mary University of London, London, United Kingdom;
5Gilead Sciences, Inc., Foster City, California, USA; 6Pharpoint Research, Inc., Durham, North Carolina, USA; 7Centre Hospitalier Universitaire-Estaing, Université d'Auvergne, Clermont-Ferrand, France; 8King's College Hospital, London, United Kingdom; 9Gastro One, Germantown, Tennessee, USA; 10Auckland Clinical Studies, Auckland, New Zealand
|
| |
|
|
|
|
|
